Please ensure Javascript is enabled for purposes of website accessibility

Iovance Biotherapeutics Couples Data Release With Stock Offering

By Maxx Chatsko – May 28, 2020 at 1:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.

What happened

Shares of Iovance Biotherapeutics (IOVA 1.01%) fell as much as 15.7% today after the company announced a proposed public offering of common stock. The development-stage biopharma is looking to raise up to $575 million in gross proceeds. Although pricing has yet to be announced, an offering of that magnitude would lead to a roughly 15% increase in the number of shares outstanding. 

News of the proposed stock offering was coupled with the release of new clinical data for lifileucel in advanced melanoma. In the C-144-01 study, the first 68 patients in cohort 4 achieved an overall response rate (ORR) of 32.4% at a median follow-up of 5.3 months. In cohort 2, the median duration of response (how long patients maintain a response without relapse or death) had not been reached at 18.7 months of follow up. The ORR in cohort 2 was 36.4%. 

Of course, investors are widely expecting lifileucel to earn regulatory approval in the near future, which helps to explain why the encouraging data didn't offset concerns of significant dilution from the stock offering. As of 12:42 p.m. EDT, the pharma stock had settled to a 13.7% loss.

A chart on a chalkboard showing steady gains and then a sudden fall.

Image source: Getty Images.

So what

Iovance Biotherapeutics is developing a pipeline of cell therapies taking aim at cancers. The lead drug candidates are tumor infiltrating lymphocytes (TILs), although earlier-stage assets now include peripheral-blood lymphocytes (PBLs) and an interleukin-2 analog. The company is widely expected to earn regulatory approval for lifileucel in advanced melanoma and LN-145 in advanced cervical cancer.

In recent months, rumors swirled that the biopharma had been approached for a potential buyout, but today's public offering of common stock suggests Iovance Biotherapeutics is preparing to make the transition to commercial-stage operations without a sale. That could be another factor weighing on shares today.

Now what

Investors with a long-term mindset might not mind the stock offering, although it will result in a significant amount of dilution. The business ended March with $240 million in cash, cash equivalents, and short-term investments. Adding another $575 million in gross proceeds from the public stock offering would allow Iovance Biotherapeutics to hit the ground running with potential drug launches and invest in early stage assets. 

Maxx Chatsko owns shares of Iovance Biotherapeutics, Inc. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
$9.95 (1.01%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.